CSPC

Biomarkers

• ALK fusion2
• EGFR exon 19 deletion / L858R1
• HER2 (ERBB2) activating mutation1
• FLT3 mutation (ITD/TKD)1
• ROS1 fusion1
• NTRK1/2/3 fusion1
• NRG1 fusion1

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

SYS6010 4osimertinib 2

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

• 2026-11 A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer Phase 2 · EGFR exon 19 deletion / L858R
• 2026-12 A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC Phase 3 · EGFR exon 19 deletion / L858R
• 2027-07 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors Phase 1/2 · HER2 (ERBB2) activating mutation

Trials

8 of 17 trials shown

1. A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

   Not yet recruiting Phase 3 CSPC Started 2026Primary completion 2026-12 NCT07376382

   SYS6010osimertinib FDA EUpemetrexed

   Carry at least one EGFR-sensitive mutation (ex19del or L858R, which can be combined with other EGFR mutations).

   EGFR exon 19 deletion / L858RNSCLC

2. SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

   Not yet recruiting Phase 3 CSPC Started 2026Primary completion 2027-12 NCT07442565

   SYS6010docetaxel

   EGFR mutations (currently approved by regulatory authorities for targeted therapy) must be confirmed neg…

   EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer

3. Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

   Recruiting Phase 3 CSPC Started 2025Primary completion 2026-07 NCT06927986

   SYS6010pemetrexedcisplatincarboplatin

   Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

   EGFR exon 19 deletion / L858REGFR-mutated Locally Advanced or Metastatic NSCLC

4. Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

   Active, not recruiting Phase 3 CSPC Started 2021Primary completion 2027-12 NCT04668690

   mitoxantroneChidamide

   ALK+ systematic anaplastic large T-cell lymphoma (ALCL, ALK+);

   ALK fusionPeripheral T Cell Lymphoma

5. A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

   Not yet recruiting Phase 2 CSPC Started 2025Primary completion 2026-11 NCT07256509

   SYS6010osimertinib FDA EUpemetrexedcisplatincarboplatin

   …mbined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

   EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer

6. Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors

   Active, not recruiting Phase 1/2 CSPC Started 2025Primary completion 2027-07 NCT07122063

   SYS6045

   …metastatic solid tumors (excluding breast, colorectal, and NSCLC), with HER2 expressionor HER2 mutation.

   HER2 (ERBB2) activating mutationAdvanced Solid Tumors

7. SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

   Recruiting Phase 1/2 CSPC Started 2021Primary completion 2024-10 NCT05445154

   SKLB1028 Dose Escalation

   Subjects who are positive for FLT3 mutations by central laboratory;

   FLT3 mutation (ITD/TKD)Status may be outdated, last updated 2022-07-06Newly Diagnosed Acute Myeloid Leukemia (AML)

8. A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors

   Recruiting Phase 1 CSPC Started 2024Primary completion 2026-10 NCT07110883

   SYS6023

   …r (PR) ) expression for breast cancer participants, and Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic Lymphoma Kinase (ALK) fusion, ROS Proto-Oncogene 1, receptor tyrosine kinase …

   EGFR exon 19 deletion / L858RKRAS G12CBRAF V600EMET exon 14 skippingALK fusionROS1 fusionRET fusion or mutationNTRK1/2/3 fusionNRG1 fusionAdvanced Solid Tumor

No trials match these filters.